Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sun Lays Out Halol Compliance Plan As Results Trounce Forecasts

This article was originally published in PharmAsia News

Executive Summary

India’s Sun Pharma has surprised investors with a strong leap in profit and it says it will lodge a request by the end of June with the US FDA to re-inspect its troubled Halol plant, in the first official indication of a likely timeline for the restoration of compliance at the facility.


Related Content

Analysts Cut Sun Forecasts After New Halol Site Faults


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst